Fortress Biotech and Urica Therapeutics Report First Patient Doses in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for Gout Treatment

Clinical Trials Initiation: Urica Therapeutics announced the dosing of first patients in two Phase 3 trials (RUBY and TOPAZ) for dotinurad, a new oral treatment for gout, aiming to evaluate its safety and efficacy compared to allopurinol.

Significance of Trials: The initiation of these trials is seen as a crucial step towards expediting the development and regulatory approval of dotinurad, addressing a significant unmet need for patients with gout who do not respond to existing treatments.

Company Background: Urica is a subsidiary of Fortress Biotech, which has a diverse portfolio of pharmaceutical products and is focused on enhancing shareholder value through strategic development and partnerships.

Gout Overview: Gout is a common and debilitating form of arthritis caused by excess uric acid, leading to painful inflammation. Current treatment options are limited, highlighting the importance of new therapies like dotinurad.